772 related articles for article (PubMed ID: 17016557)
1. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
[TBL] [Abstract][Full Text] [Related]
2. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.
Sennino B; Falcón BL; McCauley D; Le T; McCauley T; Kurz JC; Haskell A; Epstein DM; McDonald DM
Cancer Res; 2007 Aug; 67(15):7358-67. PubMed ID: 17671206
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.
Inai T; Mancuso M; Hashizume H; Baffert F; Haskell A; Baluk P; Hu-Lowe DD; Shalinsky DR; Thurston G; Yancopoulos GD; McDonald DM
Am J Pathol; 2004 Jul; 165(1):35-52. PubMed ID: 15215160
[TBL] [Abstract][Full Text] [Related]
4. Imaging tumor angiogenesis.
Red-Horse K; Ferrara N
J Clin Invest; 2006 Oct; 116(10):2585-7. PubMed ID: 17016553
[TBL] [Abstract][Full Text] [Related]
5. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.
Nakahara T; Norberg SM; Shalinsky DR; Hu-Lowe DD; McDonald DM
Cancer Res; 2006 Feb; 66(3):1434-45. PubMed ID: 16452199
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors.
Morikawa S; Baluk P; Kaidoh T; Haskell A; Jain RK; McDonald DM
Am J Pathol; 2002 Mar; 160(3):985-1000. PubMed ID: 11891196
[TBL] [Abstract][Full Text] [Related]
7. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.
Baffert F; Le T; Sennino B; Thurston G; Kuo CJ; Hu-Lowe D; McDonald DM
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H547-59. PubMed ID: 16172161
[TBL] [Abstract][Full Text] [Related]
8. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Sennino B; Kuhnert F; Tabruyn SP; Mancuso MR; Hu-Lowe DD; Kuo CJ; McDonald DM
Cancer Res; 2009 May; 69(10):4527-36. PubMed ID: 19401451
[TBL] [Abstract][Full Text] [Related]
9. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
Fenton BM; Paoni SF
Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
[TBL] [Abstract][Full Text] [Related]
10. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors.
Baluk P; Morikawa S; Haskell A; Mancuso M; McDonald DM
Am J Pathol; 2003 Nov; 163(5):1801-15. PubMed ID: 14578181
[TBL] [Abstract][Full Text] [Related]
11. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
Pernasetti F; Nickel J; Clark D; Baeuerle PA; Van Epps D; Freimark B
Int J Oncol; 2006 Dec; 29(6):1371-9. PubMed ID: 17088974
[TBL] [Abstract][Full Text] [Related]
12. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.
You WK; Sennino B; Williamson CW; Falcón B; Hashizume H; Yao LC; Aftab DT; McDonald DM
Cancer Res; 2011 Jul; 71(14):4758-68. PubMed ID: 21613405
[TBL] [Abstract][Full Text] [Related]
13. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.
Osusky KL; Hallahan DE; Fu A; Ye F; Shyr Y; Geng L
Angiogenesis; 2004; 7(3):225-33. PubMed ID: 15609077
[TBL] [Abstract][Full Text] [Related]
14. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
Greenberg JI; Shields DJ; Barillas SG; Acevedo LM; Murphy E; Huang J; Scheppke L; Stockmann C; Johnson RS; Angle N; Cheresh DA
Nature; 2008 Dec; 456(7223):809-13. PubMed ID: 18997771
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
Coutelle O; Schiffmann LM; Liwschitz M; Brunold M; Goede V; Hallek M; Kashkar H; Hacker UT
Br J Cancer; 2015 Feb; 112(3):495-503. PubMed ID: 25562438
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy: creating a unique "window" of opportunity.
Lin MI; Sessa WC
Cancer Cell; 2004 Dec; 6(6):529-31. PubMed ID: 15607955
[TBL] [Abstract][Full Text] [Related]
17. Type IV collagen alpha6 chain-derived noncollagenous domain 1 (alpha6(IV)NC1) inhibits angiogenesis and tumor growth.
Mundel TM; Yliniemi AM; Maeshima Y; Sugimoto H; Kieran M; Kalluri R
Int J Cancer; 2008 Apr; 122(8):1738-44. PubMed ID: 18074349
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
Winkler F; Kozin SV; Tong RT; Chae SS; Booth MF; Garkavtsev I; Xu L; Hicklin DJ; Fukumura D; di Tomaso E; Munn LL; Jain RK
Cancer Cell; 2004 Dec; 6(6):553-63. PubMed ID: 15607960
[TBL] [Abstract][Full Text] [Related]
19. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade.
Nisancioglu MH; Betsholtz C; Genové G
Cancer Res; 2010 Jun; 70(12):5109-15. PubMed ID: 20501841
[TBL] [Abstract][Full Text] [Related]
20. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.
Franco M; Pàez-Ribes M; Cortez E; Casanovas O; Pietras K
Horm Metab Res; 2011 Nov; 43(12):884-9. PubMed ID: 21960459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
